Every score Oncera Plus produces does one job: help you choose the right immunotherapy for the right patient, using the workup you already have in front of you.
Results in minutes, at the point of care — not days. The model runs on data already in the chart, so there's no lab turnaround to wait on. The risk estimate is ready in time for the conversation you're already having with your patient, not a follow-up call after they've gone home.
Built to sit alongside your existing clinical documentation, not replace it. Oncera Plus adds one report to the workup you're already reviewing — no separate system, no new workflow to learn. Nothing to relearn or reconcile; it fits into how your clinic already runs.
Every score comes with the clinical factors that drove it attached, not a bare number. That backs up your clinical judgment instead of replacing it — you can weigh the model's reasoning against your own read of the patient.
Decision support, focused on one job: helping you choose the right immunotherapy for the right patient. The toxicity score is presented as one input among several, alongside the clinical factors that produced it. It sharpens the choice in front of you — the decision itself stays with you and your patient.
We're actively developing additional disease models beyond lung cancer and expanding our hospital partnerships to grow and diversify the clinical data behind every model we build. More models will be announced here as they become available.
Oncera Plus isn't a general-purpose AI system adapted for healthcare. It was purpose-built to calculate one thing — an individualized immunotherapy toxicity score — trained and validated on clinical outcomes from NHS partner hospitals, drawing on data from more than 3,999 patients. It's MHRA registered, and our approach has been presented at leading oncology conferences and published in the form of abstracts.
Oncera Plus was built specifically to predict immunotherapy toxicity risk, trained and validated on clinical outcomes. It is MHRA registered.
The model is built on clinical data from more than 3,999 patients, including 500+ with lung cancer who received immunotherapy.
We're currently working with a number of NHS hospitals as we expand the data behind our models.
Our approach to predicting immunotherapy response & toxicity has been presented at leading oncology conferences and published as conference abstracts.
a machine learning algorithm to predict immunotherapy response in small cell and non-small cell lung cancer
companion abstract on the same lung cancer response model
immunotherapy toxicity prediction in melanoma using machine learning
a precision-medicine approach to melanoma immunotherapy, predicting response, adverse events, and hospital admissions using explainable AI
Current model: Toxicity prediction in lung cancer. Prediction models based on other diseases will be available soon.
Register once, then log straight into your clinician workspace.
The same factors already in the patient's workup — imaging, bloodwork, clinical history. A guided form walks you through it; nothing new to test or collect.
A toxicity score in minutes, with the contributing factors laid out next to it — ready to bring straight into the conversation with your patient.
Clinical outcome data from an NHS partner hospital — approximately 3,000 patients, including around 500 with lung cancer treated with immunotherapy. We're expanding this dataset through ongoing hospital partnerships.
Oncera Plus is MHRA registered.
Here, toxicity means any immune-related side effect of any grade recorded in a patient's clinical notes during immunotherapy treatment. The score is a single probability: it does not predict which specific side effect may occur or how severe it may be.
No. It's a decision-support tool intended to sit alongside your existing clinical assessment, not replace it.
Clinical and biomarker information already collected during a standard workup — no additional testing required.
Patient and clinical data is encrypted at rest and in transit and protected through access controls. Clinical information entered through OnceraPlus is processed through CURE-IO to generate the patient’s personalised assessment and may also be used for scientific research, model validation, testing and development as described in our Privacy Policy. OnceraPlus uses third-party providers for services including cloud hosting and email, and further details about data storage, sharing, international transfers and patient rights are set out in our Privacy Policy.
Yes — see “Why trust Oncera Plus” above for our published conference abstracts.